{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:13:30Z","timestamp":1791630810535,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Subcutaneous tocilizumab (TCZ SC) is approved globally for giant cell arteritis (GCA). This phase Ib study investigated the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of intravenous (IV) TCZ 6 and 7 mg\/kg in patients with GCA. This study explored an IV dose resulting in a minimum exposure level within the range of effective trough concentrations achieved with TCZ SC dosing in GCA and not exceeding the exposure of the well-tolerated 8 mg\/kg IV every 4 weeks (Q4W) in rheumatoid arthritis (RA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with GCA who had received \u2265 5 doses of TCZ IV 8 mg\/kg Q4W and achieved remission were enrolled. Patients received 5 doses of TCZ IV 7 mg\/kg Q4W in period 1 and, if still in remission, 5 doses of 6 mg\/kg Q4W in period 2. Pharmacokinetic endpoints were maximum concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>), minimum concentration (<jats:italic>C<\/jats:italic><jats:sub>trough<\/jats:sub>), area under the curve over a dosing interval (AUC<jats:sub><jats:italic>\u03c4<\/jats:italic><\/jats:sub>), and mean concentration (<jats:italic>C<\/jats:italic><jats:sub>mean<\/jats:sub>) of TCZ after the last dose of each period. Other endpoints included pharmacodynamic markers, safety, and exploratory efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 24 patients, the median (range) age was 65.5 (57\u201390) years, and 62.5% were female. TCZ exposures (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and AUC<jats:sub><jats:italic>\u03c4<\/jats:italic><\/jats:sub>) were 11.2% and 20.0% lower at the 6- than 7-mg\/kg dose. The mean interleukin 6 (IL-6) serum concentrations were elevated at baseline and remained elevated, with slightly higher concentrations in period 1 than in period 2. The mean serum soluble IL-6 receptor concentrations were elevated at baseline and comparable between the 2 doses at steady state. C-reactive protein levels and most erythrocyte sedimentation rates were within normal ranges throughout the study. Overall, 22 patients (91.7%) had \u2265 1 adverse event, and 4 (16.7%) had a serious adverse event. No patients experienced a GCA flare, and all remained in remission throughout the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Both doses of TCZ IV Q4W were generally well tolerated in patients with GCA. The <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>C<\/jats:italic><jats:sub>mean<\/jats:sub> achieved with 6 mg\/kg IV Q4W in patients with GCA were similar to those in patients with RA treated with 8 mg\/kg IV Q4W, and <jats:italic>C<\/jats:italic><jats:sub>trough<\/jats:sub> was within the range observed in patients with GCA treated with SC dosing every week or every 2 weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, NCT03923738<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02815-9","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T01:02:44Z","timestamp":1654304564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8001-5584","authenticated-orcid":false,"given":"Christophe","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myl\u00e8ne","family":"Giraudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Zucchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Daikeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"2815_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaut.2014.01.017","volume":"48-49","author":"G Nesher","year":"2014","unstructured":"Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014;48-49:73\u20135.","journal-title":"J Autoimmun"},{"issue":"2","key":"2815_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","volume":"47","author":"CS Crowson","year":"2017","unstructured":"Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017;47(2):253\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2815_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/art.30155","volume":"63","author":"CS Crowson","year":"2011","unstructured":"Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2815_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18(1):22\u201334.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2815_CR5","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56(4):506\u201315.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2815_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2019","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2019;79(1):19\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2815_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.semarthrit.2017.12.009","volume":"48","author":"A Berti","year":"2018","unstructured":"Berti A, Cornec D, Medina Inojosa JR, Matteson EL, Murad MH. Treatments for giant cell arteritis: meta-analysis and assessment of estimates reliability using the fragility index. Semin Arthritis Rheum. 2018;48(1):77\u201382.","journal-title":"Semin Arthritis Rheum"},{"issue":"1 Suppl 70","key":"2815_CR8","first-page":"S114","volume":"30","author":"I Kotter","year":"2012","unstructured":"Kotter I, Henes JC, Wagner AD, Loock J, Gross WL. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S114\u2013S29.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2815_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328.","journal-title":"N Engl J Med"},{"issue":"10031","key":"2815_CR10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921\u20137.","journal-title":"Lancet"},{"issue":"9","key":"2815_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41584-020-0458-5","volume":"16","author":"D Camellino","year":"2020","unstructured":"Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol. 2020;16(9):481\u201395.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"2815_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C, O\u2019Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2815_CR13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3899\/jrheum.141347","volume":"42","author":"TA Kermani","year":"2015","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42(7):1213\u20137.","journal-title":"J Rheumatol"},{"issue":"8","key":"2815_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/art.40876","volume":"71","author":"JH Stone","year":"2019","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. Arthritis Rheumatol. 2019;71(8):1329\u201338.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"2815_CR15","doi-asserted-by":"publisher","first-page":"E328","DOI":"10.1016\/S2665-9913(21)00038-2","volume":"3","author":"JH Stone","year":"2021","unstructured":"Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021;3(5):E328\u2013E36.","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"2815_CR16","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF, Hern\u00e1ndez-Garc\u00eda C, Fern\u00e1ndez-Guti\u00e9rrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789\u201397.","journal-title":"Arthritis Rheum"},{"key":"2815_CR17","doi-asserted-by":"crossref","unstructured":"Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8(8):CD013484.","DOI":"10.1002\/14651858.CD013484.pub2"},{"issue":"4","key":"2815_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/03009742.2019.1571223","volume":"48","author":"C Turesson","year":"2019","unstructured":"Turesson C, B\u00f6rjesson O, Larsson K, Mohammad AJ, Knight A. Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. Scand J Rheumatol. 2019;48(4):259\u201365.","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"2815_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/acr.24632","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021;73(8):1071\u201387.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2815_CR20","unstructured":"ACTEMRA Prescribing Information. Genentech, Inc. South San Francisco, CA. 2021."},{"issue":"7","key":"2815_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/0091270009350623","volume":"50","author":"N Frey","year":"2010","unstructured":"Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754\u201366.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"2815_CR22","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364.","journal-title":"Blood"},{"issue":"1","key":"2815_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40744-019-0139-5","volume":"6","author":"S Gale","year":"2019","unstructured":"Gale S, Trinh H, Tuckwell K, Collinson N, Stone JH, Sarsour K, et al. Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: analyses of tocilizumab clinical trials and claims data. Rheumatol Ther. 2019;6(1):77\u201388.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"2815_CR24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.autrev.2018.07.004","volume":"17","author":"GM Rossi","year":"2018","unstructured":"Rossi GM, Mannoni A, Di Scala G, Silvestri E, Cojan RD, Vannozzi L, et al. Low-dose tocilizumab for relapsing giant cell arteritis in the elderly, fragile patient: beyond the GiACTA trial. Autoimmun Rev. 2018;17(12):1265\u20137.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2815_CR25","doi-asserted-by":"publisher","first-page":"rkaa017","DOI":"10.1093\/rap\/rkaa017","volume":"4","author":"F Regola","year":"2020","unstructured":"Regola F, Cerudelli E, Bosio G, Andreoli L, Tincani A, Franceschini F, et al. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatol Adv Pract. 2020;4(2):rkaa017.","journal-title":"Rheumatol Adv Pract"},{"issue":"9","key":"2815_CR26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3899\/jrheum.200952","volume":"48","author":"J Cl\u00e9ment","year":"2021","unstructured":"Cl\u00e9ment J, Duffau P, Constans J, Schaeverbeke T, Viallard JF, Barcat D, et al. Real-world risk of relapse of giant cell arteritis treated with tocilizumab: a retrospective analysis of 43 patients. J Rheumatol. 2021;48(9):1435\u201341.","journal-title":"J Rheumatol"},{"issue":"9","key":"2815_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","volume":"58","author":"S Adler","year":"2019","unstructured":"Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford). 2019;58(9):1639\u201343.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02815-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T01:05:10Z","timestamp":1654304710000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02815-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2815"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02815-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave informed consent. This study was conducted in accordance with the International Council for Harmonisation E6 Guideline for Good Clinical Practice and the Declaration of Helsinki or Swiss regulations, whichever afforded greater patient protection. The protocol was approved by the ethics committee of the participating institution (Ethikkommission Nordwest- und Zentralschweiz, Basel, and Kantonale Ethikkommission Bern KEK, Bern).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CS: employee and stockholder of F. Hoffmann-La Roche Ltd. LB: employee of F. Hoffmann-La Roche Ltd. MG: employee of F. Hoffmann-La Roche Ltd. MZ: working for F. Hoffmann-La\u00a0Roche Ltd. as an employee of Parexel International. LC: research\/nonfinancial support, advisory fees, and stock ownership from Bristol\u00a0Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Novartis, Pfizer, and Sanofi. BB: no disclosures. TD: speaker and advisory fees and research support from Novartis. PMV: speaker and advisory fees and research support from Roche, MSD, AbbVie, Pfizer, Novartis, Gr\u00fcnenthal, Amgen, Sanofi, Chugai, BMS, and Gilead.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}